We investigated whether the SCFA-FFAR2/3-GLP-1 pathway is important for protection against intestinal disease utilising dual-receptor FFAR2/3 KO mice treated with DSS for 7 days and hypothesised that FFAR2/3 KO mice would present with severe colitis. Here, GLP1R is linked to intestinal disorder.